Business Context and Reporting Period
This Form 8-K filing by Zura Bio Ltd (Nasdaq: ZURA) covers events occurring on February 21, 2026, with the report dated February 23, 2026. The company, incorporated in the Cayman Islands, is an emerging growth company focused on biotechnology. The filing primarily addresses changes to the Board of Directors and related compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $40,000 per director (prorated based on days served).
- Initial Option Grant Value Cap: $200,000 per director.
- Option Grant Share Limit: Lesser of 51,000 Class A Ordinary Shares or the number resulting in the $200,000 value cap.
Material Changes
The filing reports significant changes to the composition of the Board of Directors effective February 21, 2026:
- Resignation: Neil Graham resigned from the Board. The resignation was not due to any disagreement with the Company regarding operations, policies, practices, or strategy.
- Appointments: The Board appointed Dr. Mark Eisner and Dr. Ajay Nirula as directors effective immediately.
- Compensation Structure: New directors received initial stock option grants vesting over 12 months, with accelerated vesting provisions tied to the next Annual General Meeting.
Outlook, Risks, and Management Commentary
The filing includes a Regulation FD disclosure referencing a press release issued on February 23, 2026 (Exhibit 99.1), though the specific content of that release is not detailed in the text provided. No specific guidance, risks, or contingencies regarding the company's operational outlook are disclosed in this document. The text confirms no family relationships or undisclosed material interests exist between the new directors and other company officers.
Investor Verification Checklist
- Verify the full text of the press release dated February 23, 2026 (Exhibit 99.1) for additional context on the board changes.
- Confirm the current share price to calculate the exact number of shares underlying the $200,000 option value cap for the new directors.
- Review the company's 2023 Equity Incentive Plan to understand the full terms of the stock option grants.
- Check subsequent filings for the date of the next Annual General Meeting to determine the accelerated vesting timeline.